Skip to main content

Table 1 Association of PD-L1 staining with clinicopathologic factors in all patients without neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

  TC TCIC IC sTIL level
Factors Negative Positive Fisher Negative Positive Fisher Negative Positive Fisher Low High Fisher
N (%) N (%) P value N (%) N (%) P value N (%) N (%) P value N (%) N (%) P value
Age [N = 341]   [N = 340]   [N = 340]   [N = 345]  
 < 50 years 81 (88) 11 (12) 0.5411 68 (75) 23 (25) 0.2256 71 (78) 20 (22) 0.1466 60 (63) 35 (37) 0.0153
 ≥ 50 years 226 (91) 23 (9)   202 (81) 47 (19)   211 (85) 38 (15)   191 (76) 59 (24)  
Race/ethnicity [N = 341]   [N = 340]   [N = 340]   [N = 345]  
 Black 34 (83) 7 (17) 0.1159 20 (49) 21 (51) < 0.0001 21 (51) 20 (49) < 0.0001 17 (41) 24 (59) < 0.0001
 White+Latino 257 (91) 24 (9)   235 (84) 45 (16)   246 (88) 34 (12)   219 (77) 66 (23)  
 Others 16 (84) 3 (16)   15 (79) 4 (21)   15 (79) 4 (21)   15 (79) 4 (21)  
Histologic type [N = 340]   [N = 339]   [N = 339]   [N = 344]  
 IDC 261 (90) 29 (10) 1 225 (78) 64 (22) 0.262 233 (81) 56 (19) 0.0121 200 (68) 92 (32) < 0.0001
 ILC 34 (89) 4 (11)   34 (89) 4 (11)   37 (97) 1 (3)   36 (95) 2 (5)  
 Metaplastic 0 (0) 0 (0)   0 (0) 0 (0)   0 (0) 0 (0)   0 (0) 0 (0)  
 Mixed IDC/ILC 11 (92) 1 (8)   10 (83) 2 (17)   11 (92) 1 (8)   14 (100) 0 (0)  
Histologic grade [N = 340]   [N = 339]   [N = 339]   [N = 344]  
 1 + 2 216 (96) 10 (4) < 0.0001 200 (88) 26 (12) < 0.0001 208 (92) 18(8) < 0.0001 201 (87) 30 (13) < 0.0001
 3 90 (79) 24 (21)   69 (61) 44 (39)   73 (65) 40 (35)   49 (43) 64 (57)  
sTIL level [N = 337]   [N = 337]   [N = 337]   NA  
 < 10% 233 (95) 12 (5) < 0.0001 226 (92) 19 (8) < 0.0001 235 (96) 10 (4) < 0.0001    
 ≥ 10% 70 (76) 22 (24)   42 (46) 50 (54)   44 (48) 48 (52)     
ER [N = 341]   [N = 340]   [N = 340]   [N = 345]  
 Negative 60 (86) 10 (14) 0.1828 46 (66) 24 (34) 0.0026 48 (69) 22 (31) 0.0011 27 (39) 43 (61) < 0.0001
 Positive 247 (91) 24 (9)   224 (83) 46 (17)   234 (87) 36 (13)   224 (81) 51 (19)  
PR [N = 341]   [N = 340]   [N = 340]   [N = 342]  
 Negative 95 (84) 18 (16) 0.0125 73 (65) 40 (35) < 0.0001 78 (69) 35 (31) < 0.0001 54 (48) 59 (52) < 0.0001
 Positive 212 (93) 16 (7)   197 (87) 30 (13)   204 (90) 23 (10)   197 (85) 35 (15)  
HER2 [N = 338]   [N = 337]   [N = 337]   [N = 342]  
 Negative 278 (91) 29 (9) 0.2195 248 (81) 58 (19) 0.0178 257 (84) 49 (16) 0.0801 231 (75) 78 (25) 0.0071
 Positive 26 (84) 5 (16)   19 (61) 12 (39)   22 (71) 9 (29)   17 (52) 16 (48)  
TNBC [N = 338]   [N = 337]   [N = 337]   [N = 342]  
 No 250 (90) 28 (10) 1 226 (81) 52 (19) 0.0518 238 (86) 40 (14) 0.0069 227 (80) 56 (20) < 0.0001
 Yes 54 (90) 6 (10)   41 (69) 18 (31)   41 (69) 18 (31)   21 (36) 38 (64)  
Receptor group [N = 338]   [N = 337]   [N = 337]   [N = 342]  
 ER/PR pos 224 (91) 23 (9) 0.4491 207 (84) 40 (16) 0.0022 216 (87) 31 (13) 0.0009 210 (84) 40 (16) < 0.0001
 HER2 26 (84) 5 (16)   19 (61) 12 (39)   22 (71) 9 (29)   17 (52) 16 (48)  
 TNBC 54 (90) 6 (10)   41 (69) 18 (31)   41 (69) 18 (31)   21 (36) 38 (64)  
Tumor size [N = 340]   [N = 339]   [N = 339]   [N = 344]  
 ≤ 2 cm 176 (92) 16 (8) 0.34 157 (81) 36 (19) 0.3325 162 (84) 31 (16) 0.5449 151 (77) 46 (23) 0.0517
 > 2 to 5 cm 105 (87) 16 (13)   90 (75) 30 (25)   96 (80) 24 (20)   79 (65) 43 (35)  
 > 5 cm 25 (93) 2 (7)   22 (85) 4 (15)   23 (88) 3 (12)   20 (80) 5 (20)  
pN [N = 338]   [N = 337]   [N = 337]   [N = 342]  
 (y)pN0 207 (90) 22 (10) 0.4972 185 (80) 45 (20) 0.5121 191 (83) 39 (17) 0.882 169 (73) 62 (27) 0.9442
 (y)pN1 81 (91) 8 (9)   70 (80) 18 (20)   73 (83) 15 (17)   65 (71) 26 (29)  
 (y)pN2 10 (91) 1 (9)   8 (73) 3 (27)   9 (82) 2 (18)   8 (67) 4 (33)  
 (y)pN3 7 (78) 2 (22)   5 (63) 3 (38)   6(75) 2 (25)   6 (75) 2 (25)  
pM [N = 338]   [N = 337]   [N = 337]   [N = 342]  
 0 301 (90) 32 (10) 0.4036 265 (80) 68 (20) 1 275 (83) 58 (17) 1 245 (72) 93 (28) 1
 1 4 (80) 1 (20)   3 (75) 1 (25)   4 (100) 0 (0)   3 (75) 1 (25)  
pStage [N = 336]   [N = 335]   [N = 335]   [N = 340]  
 I 163 (92) 15 (8) 0.2829 150 (84) 29 (16) 0.1412 156 (87) 23 (13) 0.1034 142 (78) 40 (22) 0.0637
 II 111 (90) 13 (10)   92 (75) 31 (25)   95 (77) 28 (23)   80 (65) 44 (35)  
 III 24 (83) 5 (17)   21 (72) 8 (28)   23 (79) 6 (21)   22 (73) 8 (27)  
 IV 4 (80) 1 (20)   3 (75) 1 (25)   4 (100) 0 (0)   3 (75) 1 (25)  
  1. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, sTIL stromal tumor infiltrating lymphocytes, ER estrogen receptor, PR progesterone receptor, pos positive, TNBC triple-negative breast cancer